First

STAMFORD, Conn., 13. Januar 2025 /PRNewswire/ - Trillium Flow Technologies („Trillium"), ein Portfoliounternehmen von First Reserve und ein globaler Entwickler, Hersteller und Anbieter von Aftermarket-Dienstleistungen für…
Weiterlesen...

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 13.01.2025 / 16:17 CET/CEST The issuer is solely responsible for the content of this…
Weiterlesen...

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 13.01.2025 / 13:50 CET/CEST The issuer is solely responsible for the content of this…
Weiterlesen...

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 13.01.2025 / 13:22 CET/CEST The issuer is solely responsible for the content of this…
Weiterlesen...

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 10.01.2025 / 17:24 CET/CEST The issuer is solely responsible for the content of this…
Weiterlesen...

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 10.01.2025 / 15:00 CET/CEST The issuer is solely responsible for the content of this…
Weiterlesen...

Von München nach Zug in der Schweiz: Mit Wirkung ab dem 1. Januar 2025 wechselt der bisherige Geschäftsführer der Pangaea Life GmbH Daniel Regensburger (38) zur 2023 gegründeten Pangaea Life Capital Partners AG (PLCP). Dort leitet er…
Weiterlesen...

Permedio LifestyleChecks schaffen die Grundlage, Gesundheitsziele effektiv zu erreichen JOHN HARRIS FITNESS, ÖSTERREICHS FÜHRENDER PREMIUMANBIETER IM BEREICH FITNESS UND GESUNDHEIT, HEBT SEIN ANGEBOT ERNEUT AUF EIN NEUES…
Weiterlesen...

BIAL, a hundred-year-old innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, announced that the first patient has completed the full dose regimen in the ACTIVATE Phase 2 study. BIA 28-6156 is a…
Weiterlesen...

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 31.12.2024 / 15:00 CET/CEST The issuer is solely responsible for the content of this…
Weiterlesen...